In an interview with PharmaShots, Jonathan Rigby, Group Chief Executive Officer at Revolo Biotherapeutics shared his views on the unique mechanism of '1104 and discuss the plan of the company's clinical studies.
Shots:
Revolo reported the US FDA's approval to initiate a P-II clinical trial evaluating the safety and efficacy of '1104 in adults with EoE
'1104 is a…
